The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | Unmet needs and challenges that remain in treating patients with SCD in SSA
Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, outlines the unmet needs and remaining challenges in treating patients with sickle cell disease (SCD) in sub-Saharan Africa (SSA). Prof. Tshilolo highlights that insufficient funding and a lack of concern from policymakers make implementing a comprehensive management program challenging. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novo Nordisk, Pfizer.
